'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
about
Recent advances in understanding multiple myelomaA practical review on carfilzomib in multiple myeloma.Comprehensive review on cardio-oncology: Role of multimodality imaging.Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.Safety issues and management of toxicities associated with new treatments for multiple myeloma.Integration of Novel Agents into the Care of Patients with Multiple Myeloma.Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events.The proteasome and proteasome inhibitors in multiple myeloma.Cardiovascular complications of multiple myeloma in the elderly.Cardiotoxicity with carfilzomib at doses greater than 27 mg/m(2): A case series.Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib.Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural History and Risk Factors.Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights.An overview of the role of carfilzomib in the treatment of multiple myeloma.
P2860
Q28070331-77BFBCA2-C5AC-4A5A-A182-98EB59D71AFEQ38740271-DD91A413-965B-4BA0-BBF1-669B27BF3627Q38844387-54512AD4-E69B-4638-A76D-0FB079F5D242Q39022303-5169DE32-B317-4F5F-ACD9-5F115410BF5AQ39100317-5E8788BF-AD1C-4798-A94B-2EFC87D9881DQ46754093-12F5FBC1-9948-484D-84B4-6524BF1292CAQ47102326-3DA0ADD3-F3A3-4DC3-BC1E-D0ABAD6E97BBQ47339695-E859EB99-1B1D-4A03-9CE9-CABB3026ADABQ47374630-48986B27-4F89-47C7-BE31-6434C6A7DB3DQ47980047-AFC81A02-DE09-4561-8609-FB5239FE2525Q48170012-3A3DAF90-F289-480E-B0C0-3EFCF04229E8Q48206067-6869BD9E-CA6F-474B-B1AB-8540D566AE33Q48296982-4B43375B-5CDE-4A83-BEA7-49366327797BQ49315568-48F25DD1-C321-423F-8602-162016FF58B6Q50035012-E8252AB8-C4E3-4543-8E6A-8C28DD874117
P2860
'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
'Real-life' experience of prea ...... city and predisposing factors.
@en
type
label
'Real-life' experience of prea ...... city and predisposing factors.
@en
prefLabel
'Real-life' experience of prea ...... city and predisposing factors.
@en
P2093
P2860
P356
P1476
'Real-life' experience of prea ...... city and predisposing factors.
@en
P2093
Leo Rasche
Martin Schreder
Sophia Danhof
Stefan Knop
Susanne Strifler
P2860
P356
10.1111/EJH.12677
P577
2015-09-02T00:00:00Z